# ClinicalTrials.gov record NCT01667900

> PeptideScanner retained ClinicalTrials.gov record NCT01667900 at 2026-07-30T21:38:42.858Z. Its registry update date was 2016-03-07, and PeptideScanner's reviewed identity mapping was dulaglutide.

- Evidence object: `story:clinicaltrials-gov-nct01667900-dulaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-03-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01667900-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01667900-dulaglutide-v1.json
- Content SHA-256: `e71f3c8ea39d10bbfc4762ed326d90072e7d7a44221d11f08b8ee400d266dfd9`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT01667900 ([`ctg-observation-nct01667900-2016-03-07-9a22543dbac4`](#source-ctg-observation-nct01667900-2016-03-07-9a22543dbac4))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01667900 at 2026-07-30T21:38:42.858Z. Its registry update date was 2016-03-07, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct01667900-2016-03-07-9a22543dbac4`](#source-ctg-observation-nct01667900-2016-03-07-9a22543dbac4))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01667900 at 2026-07-30T21:38:42.858Z. Its registry update date was 2016-03-07, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct01667900-2016-03-07-9a22543dbac4`](#source-ctg-observation-nct01667900-2016-03-07-9a22543dbac4))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01667900-2016-03-07-9a22543dbac4`](#source-ctg-observation-nct01667900-2016-03-07-9a22543dbac4))

## Sources

<a id="source-ctg-observation-nct01667900-2016-03-07-9a22543dbac4"></a>
- **ClinicalTrials.gov record NCT01667900 · retained source version 2016-03-07:9a22543dbac4de18fff3f7280d13b42b3fddb2bae3dd2803d2d7a11e69812de3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01667900) (`ctg-observation-nct01667900-2016-03-07-9a22543dbac4`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01667900." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01667900-dulaglutide-v1.json SHA-256: e71f3c8ea39d10bbfc4762ed326d90072e7d7a44221d11f08b8ee400d266dfd9.